MICROWAVE ABLATION IN COMBINED TREATMENT OF PRIMARY AND METASTATIC LIVER TUMORS

Aim. To increase the effectiveness of treatment of patients with primary and metastatic liver cancer.

Material and Methods. Microwave ablation was performed in 29 patients including 13 cases of hepatocellular carcinoma stage 0-A (byBarcelona classification and TNM) and 16 patients with colorectal cancer and liver metastases stage I (by Gennari). For microwave ablation of liver tumors AveCure MWG881 (MedWaves) device was used. Procedure was performed via percutaneous transhepatic approach (25), under ultrasonic guidance and intraoperatively simultaneously with liver resection in 4 cases. Effectiveness was estimated using CT and sonography.

Results. There were no deaths. We observed following complications: moderate bleeding from the point of needle catheter entry that has stopped independently in 1 case; residual cavity formed in one case that did not require additional surgery. Intrahepatic hematoma was diagnosed in 1 case. Burns of the skin were revealed in 2 cases. The average hospital stay was 7 days. Local recurrences after ablation were not observed. 1- and 2-year survival was 78.5% and 63.3% respectively.

Conclusion. Microwave ablation in patients with primary and secondary liver cancer and concomitant cirrhosis increases 1- and 2-year survival. Percutaneous microwave ablation reduces the incidence of complications in high risk patients due to low invasiveness and less trauma.

1. Liu L.X., Zhang W.H., Jiang H.C. Current treatment for liver metastases from colorectal cancer. World J. Gastroenterol. 2003; 9 (2): 193–200.

2. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of hepatocellular carcinoma. Hepatology. 2005; 42 (5): 1208–1236.

3. Adam R., Akpinar E., Johann M. Place of cryosurgery in the treatment of malignant liver tumors. Ann. Surg. 1997; 225 (1): 39–50.

4. Graziadei I.W., Sandmueller H., Waldenberger P., Koenigsrainer A. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003; 9 (6): 557–563.

5. Salem R., Lewandowski R.J., Atassi B., Gordon S.C. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J. Vasc. Interv. Radiol. 2005; 16 (12): 1627–1639.

6. Veenendaal L.M., van Hillegersberg R., Smakman N., van der Bilt J.D., van Diest P.J., Kranenburg O., Borel Rinkes I.H. Synergistic effect of interstitial laser coagulation and doxorubicin in a murine tumor recurrence model of solitary colorectal liver metastasis. Ann. Surg. Oncol. 2006; 13 (2): 168–175.

7. Борсуков А.В., Момджян Б.К., Коваленко Е.С., Евдокимов А.Н. Электрохимический лизис как метод локальной деструкции первичного рака печени под контролем ультразвукового исследования (в эксперименте). Медицинская визуализация. 2007; 2: 64–69. Borsukov A.V., Momdzhyan B.K., Kovalenko E.S., Evdokimov A.N. Electrochemical lysis as method of local destruction of primary liver cancer under ultrasonic control. Meditsinskaya vizualizatsiya. 2007; 2: 64–69. (In Russian)

8. Борсуков А.В., Матвеев Н.Л., Сергеева О.Н., Алиханов Р.Б. Электрохимический лизис в эксперименте и в сравнительной характеристике с радиочастотной аблацией при лечении злокачественных новообразований в печени. Эндоскопическая хирургия. 2009; 2: 19–27. Borsukov A.V., Matveev N.L., Sergeeva O.N., Alikhanov R.B. Electrochemical lysis in experiment and comparative characterization with radiofrequency ablation in the treatment of malignant liver tumors. Endoskopicheskaia khirurgiia. 2009; 2: 19–27. (In Russian)

9. Wemyss-Holden S.A., Robertson G.S., Dennison A.R., de la M. Hall P., Fothergill J.C., Jones B., Maddern G.J. Electrochemical lesions in the rat liver support its potential for tresatment of liver tumors. J. Surg. Res. 2000; 93 (1): 55–62.

10. Gervais D.A., Goldberg S.N., Brown D.B., Soulen M.C., Millward S.F., Rajan D.K. Society of Interventional Radiology Position Statement on Percutaneous Radiofrequency Ablation for the Treatment of Liver Tumors. J. Vasc. Interv. Radiol. 2009; 20 (7, Suppl.): S342–347. doi: 10.1016/j.jvir.2009.04.029.

11. Gillams A.R., Lees W.R Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur. Radiol. 2009; 19 (7): 1206–1213.

12. Jones C., Badger S.A., Ellis G. The role of microwave ablation in the management of hepatic colorectal metastases. Surgeon. 2011; 9 (1): 33–37. doi: 10.1016/j.surge.2010.07.009.

13. Wolf F., Dupuy D.E. MWA: Mechanism of action and devices. In: Hong K., Georgiades C.S. Percutaneous tumor ablation. Strategies and techniques. 2011. P. 27–44.

14. Taylor I. Colorectal liver metastases: to treat or not to treat? Br. J. Surg. 1985; 72 (7): 511– 516.